Primary aldosteronism in hypertensive patients: Clinical implications and target therapy

European Journal of Clinical Investigation

Volumn 44, Issue 8, 2014, Pages 697-706

  Papanastasiou, Labrini ^a   Markou, Athina ^a   Pappa, Theodora ^a   Gouli, Aggeliki ^a   Tsounas, Panagiotis ^a   Fountoulakis, Stelios ^a   Kounadi, Theodora ^a   Tsiama, Vasiliki ^a   Dasou, Aikaterini ^a   Gryparis, Alexandros ^b   Samara, Christianna ^a   Zografos, George ^a   Kaltsas, Gregory ^b   Chrousos, George ^b   Piaditis, George ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aldosterone; Hypertension; Primary aldosteronism

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; DEXAMETHASONE; EPLERENONE; FLUDROCORTISONE ACETATE; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM ION; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEXAMETHASONE SUPPRESSION TEST; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD; COMPLICATION; HYPERALDOSTERONISM; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN; TREATMENT OUTCOME;

EID: 84904564137     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12286     Document Type: Article

References (40)

1. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8.
2. Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000;85:1863-7.
3. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36.
4. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21:2149-57.
5. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045-50.
6. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300.
7. Takeda Y, Karashima S, Yoneda T. Primary aldosteronism, diagnosis and treatment in Japan. Rev Endocr Metab Disord 2011;12:21-5.
8. Westerdahl C, Bergenfelz A, Isaksson A, Nerbrand C, Valdemarsson S. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim Health Care 2011;29:57-62.
9. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012;167:7-15.
10. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-5.
11. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17:349-52.
12. Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012;28:318-25.
13. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999;33:261-6.
14. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-7.
15. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103:425-31.
16. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232-8.
17. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011;34:98-102.
18. Markou A., Pappa T., Kaltsas G, Gouli A, Mitsakis K, Tsounas P et al. Evidence of primary aldosteronism secretion in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013;98:1409-16.
19. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
20. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006;91:2618-23.
21. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007;66:607-18.
22. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011;41:1227-36.
23. Crabbe J, Reddy WJ, Ross EJ, Thorn GW. The stimulation of aldosterone secretion by adrenocorticotropic hormone (ACTH). J Clin Endocrinol Metab 1959;19:1185-91.
24. Arvat E, Di Vito L, Lanfranco F, Maccario M, Baffoni C, Rossetto R et al. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab 2000;85:3141-6.
25. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2012;350:151-62.
26. Sahin M, Kebapcilar L, Taslipinar A, Azal O, Ozgurtas T, Corakci A et al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing's syndrome in obese patients. Intern Med 2009;48:33-9.
27. Pappa T, Papanastasiou L, Kaltsas G, Markou A, Tsounas P, Androulakis I et al. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of aldosterone in arterial hypertension. J Clin Endocrinol Metab 2012;97:E537-45.
28. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854-9.
29. Piaditis GP, Kaltsas GA, Androulakis II, Gouli A, Makras P, Papadogias D et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009;71:772-8.
30. Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V et al. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1998;48:627-33.
31. Clarke D, Wilkinson R, Johnston ID, Hacking PM, Haggith JW. Severe hypertension in primary aldosteronism and good response to surgery. Lancet 1979;1:482-5.
32. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007;50:911-8.
33. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012;168:75-81.
34. Catena C, Colussi G, Sechi LA. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol 2012;168:C1-C5.
35. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004;89:2736-40.
36. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008;51:432-9.
37. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008;2:462-8.
38. Funder JW. Primary aldosteronism: are we missing the wood for the trees? Horm Metab Res 2012;44:251-3.
39. Xanthakis V, Vasan RS. Aldosterone and the risk of hypertension. Curr Hypertens Rep 2013;15:102-7.
40. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.